PIH Urges Further Steps to Ensure TB Drugs Available to All
Joins John Green in asking Johnson & Johnson to make details of Stop TB deal public
Posted on July 13, 2023
As an organization that believes passionately in bringing the benefits of modern medical science to those most in need of them, PIH is cautiously optimistic after hearing today that Johnson & Johnson plans to work with the Global Drug Facility, a United Nations-based procurer of medications for public health systems around the world, to open the doors to generic medication for tuberculosis. A few hours ago the Stop TB Partnership, an organization which runs the Global Drug Facility, posted a blog saying J&J had given the Facility approval to purchase and supply generic versions of bedaquiline, a key drug in treating tuberculosis, to “the majority of low-and middle-income countries.” If J&J lives up to the spirit of this agreement, bedaquiline will lower prices of TB treatment, make treatment more accessible to people, and save lives.
Many partners and friends have recognized the need for increased access to bedaquiline—TB kills some 1.6 million people each year, making it the most deadly infectious disease in the world—and have pushed for urgent action, including author and PIH trustee John Green and the Nerdfighteria community. At PIH, we will build on the work we’ve done as TB activists and clinicians—publicly and privately calling on J&J to increase access to bedaquiline, running two global clinical trials to make sure bedaquiline is prescribed in the most optimal way, and more.
Originally published on pih.org
Every person, no matter who they are or where they’re from, deserves the best health care we know how to offer.
Join us in building a more just and equitable world by making a gift today.
